Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Eva M. Horak is active.

Publication


Featured researches published by Eva M. Horak.


Cell | 1988

The CD4 and CD8 T cell surface antigens are associated with the internal membrane tyrosine-protein kinase p56lck

André Veillette; Michael A. Bookman; Eva M. Horak; Joseph B. Bolen

The CD4 and CD8 T cell antigens are thought to transduce an independent signal during the process of T cell activation. We report our evaluation of the possible involvement of the lymphocyte-specific tyrosine kinase p56lck in these transduction pathways. Our data demonstrate that p56lck is specifically modulated with either CD4 or CD8 following antibody-mediated cross-linking of these molecules and that a large fraction of the total cellular lck protein can be coimmunoprecipitated with these surface glycoproteins. These results suggest that p56lck is functionally and physically associated with CD4/CD8 in normal murine T lymphocytes and support the concept that an independent signal is transduced by the interaction of these surface molecules with major histocompatibility complex determinants.


The New England Journal of Medicine | 1987

Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis. Effect of chenodeoxycholic acid.

Gerald Salen; Vladimir M. Berginer; Virgie Shore; Ivan Horak; Eva M. Horak; G. Stephen Tint; Sarah Shefer

We investigated the effect of chenodeoxycholic acid on cerebrospinal fluid sterol and protein composition in six patients with cerebrotendinous xanthomatosis, a progressive neurologic disease, and in 11 control subjects. In the cerebrospinal fluid from the controls, the mean (+/- SD) levels of cholesterol and cholestanol were 400 +/- 300 and 4 +/- 7 micrograms per deciliter, respectively. The levels were almost 1.5 and 20 times higher in cerebrospinal fluid from untreated patients with cerebrotendinous xanthomatosis. Cholestanol levels were also markedly elevated in the plasma of untreated patients, but their plasma cholesterol levels (215 +/- 61 mg per deciliter) were not different from control values. Treatment with chenodeoxycholic acid reduced cerebrospinal fluid cholesterol by 34 percent and cholestanol threefold. Plasma cholestanol levels also decreased sharply. Normal cerebrospinal fluid contained small quantities of albumin, apolipoproteins, and lecithin:cholesterol acyltransferase. In cerebrospinal fluid from untreated patients with cerebrotendinous xanthomatosis, immunoreactive apolipoprotein B or apolipoprotein B fragment was increased about 100-fold and albumin about 3.5-fold; apolipoprotein AI, apolipoprotein D, and lecithin:cholesterol acyltransferase were 1.5 to 3 times more concentrated. Apolipoprotein AIV and apolipoprotein E concentrations were comparable to those in controls, and apolipoprotein AII was considerably decreased. During treatment, the concentrations of albumin and apolipoproteins AI and B declined. These results suggest that increased cerebrospinal fluid sterols are derived from plasma lipoproteins by means of a defective blood-brain barrier in patients with cerebrotendinous xanthomatosis. Therapy with chenodeoxycholic acid reestablished selective permeability of the blood-brain barrier and normalized the concentrations of sterol and apolipoprotein in the cerebrospinal fluid.


International Journal of Cancer | 1997

Effects of the tyrosine‐kinase inhibitor geldanamycin on ligand‐induced HER‐2/NEU activation, receptor expression and proliferation of HER‐2‐positive malignant cell lines

Frank Hartmann; Eva M. Horak; Cheryl Cho; Ruth Lupu; Joseph B. Bolen; M. A. Stetler-Stevenson; Michael Pfreundschuh; Thomas A. Waldmann; Ivan Horak

Geldanamycin belongs to the family of benzoquinoid ansamycin tyrosine‐kinase inhibitors. We have examined its effects on Her‐2/neu kinase activity, protein expression level, and proliferation of Her‐2+ malignant cells. In SK‐BR‐3 breast‐cancer cells, short‐time treatment with geldanamycin completely abrogated gp30‐ligand‐induced activation of Her‐2 without a change of receptor‐expression level. Longer treatment of intact cells with geldanamycin induced decreased steady‐state Her‐2 autophosphorylation activity, which correlated with reduction of Her‐2 protein expression and phosphotyrosine content of several proteins. The decrease was time‐ and dose‐dependent, starting after 1 hr at 100 nM concentration and reaching completion by 24 hr. The reduction of the Her‐2 protein level probably resulted from increased degradation, since the Her‐2 mRNA level remained constant. Geldanamycin effects were not specific for Her‐2, since the non‐receptor tyrosine‐kinase fyn was inhibited equally. In contrast to these results, protein‐kinase‐C activity was not affected. In 3 other malignant cell lines expressing different amounts of Her‐2 (SK‐BR‐3 > SK‐OV‐3 > OVCAR3 > MCF7), geldanamycin also effectively reduced Her‐2‐kinase activity proportionally to the decrease of protein expression. In contrast, in a [3H]‐thymidine‐uptake assay, cell growth was meaningfully inhibited by geldanamycin at nanomolar concentrations only in SK‐BR‐3 (IC50 2nM) and MCF7 (IC50 20nM), while OVCAR3 was only moderately sensitive (IC50 2μM) and SK‐OV‐3 was clearly resistant to geldanamycin. In direct comparison with herbimycin A, another benzoquinoid ansamycin that has been more thoroughly characterized, the biologic effects of geldanamycin were more pronounced. Int. J. Cancer, 70:221–229, 1997.


Nuclear Medicine and Biology | 2001

Preparation and in vivo evaluation of linkers for 211At labeling of humanized anti-Tac

Alexander T. Yordanov; Kayhan Garmestani; Meili Zhang; Zhuo Zhang; Zhengsheng Yao; K.E. Phillips; B. Herring; Eva M. Horak; M.P. Beitzel; U.P. Schwarz; Otto A. Gansow; Paul S. Plascjak; William C. Eckelman; Thomas A. Waldmann; Martin W. Brechbiel

The syntheses, radiolabeling, antibody conjugation, and in vivo evaluation of new linkers for 211At labeling of humanized anti-Tac (Hu-anti-Tac), an antibody to the alpha-chain of the IL-2 receptor (IL-2Ralpha) shown to be a useful target for radioimmunotherapy are described. Synthesis of the organometallic linker precursors is accomplished by reaction of the corresponding bromo- or iodoaryl esters with bis(tributyltin) in the presence of a palladium catalyst. Subsequent conversion to the corresponding N-succinimidyl ester and labeling with 211At of two new linkers, N-succinimidyl 4-[211At]astato-3-methylbenzoate and N-succinimidyl N-(4-[211At]astatophenethyl)succinamate (SAPS), together with the previously reported N-succinimidyl 4-[211At]astatobenzoate and N-succinimidyl 3-[211At]astato-4-methylbenzoate, are each conjugated to Hu-anti-Tac. The plasma survival times of these conjugates are compared to those of directly iodinated (125I) Hu-anti-Tac. The N-succinimidyl N-(4-[211At]astatophenethyl)succinamate compound (SAPS) emerged from this assay as the most viable candidate for 211At-labeling of Hu-anti-Tac. SAPS, along with the directly analogous radio-iodinated reagent, N-succinimidyl N-(4-[125I]astatophenethyl)succinamate (SIPS), are evaluated in a biodistribution study along with directly iodinated (125I) Hu-anti-Tac. Blood clearance and biological accretion results indicate that SAPS is a viable candidate for further evaluation for radioimmunotherapy of cancer.


Nature | 1989

Signal transduction through the CD4 receptor involves the activation of the internal membrane tyrosine-protein kinase p56lck

André Veillette; Michael A. Bookman; Eva M. Horak; Lawrence E. Samelson; Joseph B. Bolen


Cancer Research | 2001

High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.

Gregory P. Adams; Robert Schier; Adrian M. McCall; Heidi H. Simmons; Eva M. Horak; R. Katherine Alpaugh; James D. Marks; Louis M. Weiner


Proceedings of the National Academy of Sciences of the United States of America | 1991

T-lymphocyte interleukin 2-dependent tyrosine protein kinase signal transduction involves the activation of p56lck

Ivan Horak; Ronald E. Gress; P J Lucas; Eva M. Horak; Thomas A. Waldmann; Joseph B. Bolen


Archive | 2004

Bispecific antibodies for inducing apoptosis of tumor and diseased cells

Chien Hsing-chang; David M. Goldenberg; Hans J. Hansen; Eva M. Horak; Ivan Horak


The Journal of Nuclear Medicine | 1997

Radioimmunotherapy Targeting of HER2/neu Oncoprotein on Ovarian Tumor Using Lead-212-DOTA-AEl

Eva M. Horak; Frank Hartmann; Kayhan Garmestani; Chuanchu Wu; Martin W. Brechbiel; Otto A. Gansow; Nicholas F. Landolfi; Thomas A. Waldmann


Cancer Research | 1994

Radioimmunotherapy of Nude Mice Bearing a Human Interleukin 2 Receptor α-expressing Lymphoma Utilizing the α-emitting Radionuclide-conjugated Monoclonal Antibody 212Bi-anti-Tac

Frank Hartmann; Eva M. Horak; Kayhan Garmestani; Chuanchu Wu; Martin W. Brechbiel; Robert W. Kozak; J. Tso; Sheri A. Kosteiny; Otto A. Gansow; David L. Nelson; Thomas A. Waldmann

Collaboration


Dive into the Eva M. Horak's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

James D. Marks

University of California

View shared research outputs
Top Co-Authors

Avatar

Louis M. Weiner

Georgetown University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Ivan Horak

University of Würzburg

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Thomas A. Waldmann

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Michael A. Bookman

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Otto A. Gansow

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

David M. Goldenberg

Roswell Park Cancer Institute

View shared research outputs
Researchain Logo
Decentralizing Knowledge